Cholesterol accumulation beneath the retinal pigment epithelium (RPE) cells is supposed to contribute the pathogenesis of age-related macular degeneration (AMD). Cholesterol efflux genes (APOE and ABCA1) were identified as risk factors for AMD, although how cholesterol efflux influences accumulation of this lipid in sub-RPE deposits remains elusive. The 18 kDa translocator protein, TSPO, is a cholesterol-binding protein implicated in mitochondrial cholesterol transport. Here, we investigate the function of TSPO in cholesterol efflux from the RPE cells. We demonstrate in RPE cells that TSPO specific ligands promoted cholesterol efflux to acceptor (apo)lipoprotein and human serum, while loss of TSPO resulted in impaired cholesterol efflux. TSPO -/-RPE cells also had significantly increased production of reactive oxygen species (ROS) and upregulated expression of proinflammatory cytokines (IL-1b and TNFa). Cholesterol (oxidized LDL) uptake and accumulation were markedly increased in TSPO -/-RPE cells. Finally, in aged RPE cells, TSPO expression was reduced and cholesterol efflux impaired. These findings provide a new pharmacological concept to treat early AMD patients by stimulating cellular cholesterol removal with TSPO specific ligands or by overexpression of TSPO in RPE cells.
Introduction
Age-related macular degeneration (AMD) is the commonest cause of registered blindness in the developed world (1) . An important clinical feature of AMD is the accumulation of both focal (Drusen) and diffuse extracellular (basal) deposits in the macula, between the retinal pigment epithelium (RPE) and the adjacent Bruch's membrane. One current hypothesis is that these deposits lead to dysfunction and later death of RPE and associated loss of photoreceptors (2) . Ageing is associated with progressive accumulation of lipids within Bruch's membrane (3) . Lipid deposition causes hydraulic conductivity and macromolecular permeability in Bruch's membrane, which is thought to impair retinal metabolism. Histopathological analyses of AMD patients' eyes have demonstrated the presence of apolipoproteins, cholesterol and cholesteryl ester deposits underneath the RPE, implicating abnormal cholesterol transport in the progression of this disease (4) . Genome wide association studies have also implicated that hepatic lipase C (LIPC) and cholesteryl ester transfer protein (CETP), key genes involved in the metabolism of triglycerides and high-density lipoproteins (HDL), in the pathogenesis of AMD (5, 6) .
Excess cholesterol is removed from peripheral cells by the reverse cholesterol transport (RCT) pathway, by which HDL return excess cellular cholesterol to the liver for either storage as cholesteryl ester droplets or for excretion in bile. Cholesterol efflux is the first step in RCT mediated by the removal of cholesterol by acceptors, such as (apo)lipoproteins. Cholesterol efflux is mediated by ATP-binding cassette (ABC) transporters, such as ABCA1, ABCG1 and ABCG4 (7) . Our previous work in human macrophages has established that increased mitochondrial cholesterol trafficking, via the 18 kDa translocator protein (TSPO), can enhance expression of key genes encoding proteins involved in the cholesterol efflux pathway, and facilitate removal of cholesterol by apolipoprotein acceptors (8) . Transfer of cholesterol to mitochondrial sterol 27-hydroxylase (CYP27A1) increases generation of oxysterol ligands for Liver X receptors, which induce the expression of ABCA1, ABCG1/4 and ApoE.
Mitochondrial cholesterol trafficking is thought to involve a complex of proteins including TSPO, steroidogenic acute regulatory protein (StAR), the voltage dependent anion channel (VDAC) and possibly the adenine nucleotide channel (ANC), together with putative regulatory proteins (9) . The TSPO protein, previously called the peripheral-type benzodiazepine receptor, is an 18 kDa transmembrane protein localized in the outer mitochondrial membrane of different tissues. TSPO is thought to mediate a number of functions, including cholesterol transport, steriodogenesis, neuroinflammation, prevention of apoptosis and stress adaption (9) . Global or conditional Tspo knockout (KO) mouse models have been reported; the KO mice exhibited divergent phenotypes (embryonic lethal, defect in steroidogenesis, or no effect on steroidogenesis) possibly due to genetic background differences between strains of those KO mice (10) (11) (12) .
The RCT process may be important in the pathogenesis of AMD because of its involvement in lipid and cholesterol transport from RPE (13) . The RPE cells are involved in phagocytosis and degradation of photoreceptor outer segments (POS), which are thought to be the major source of excess RPE lipids. Incompletely digested POS lipids accumulate as autofluorescent lipid-protein aggregates called lipofuscin in RPE. Retinoid metabolites, such as bis-retinoids, also contribute to the formation of lipofuscin (14) . About 20% of RPE cell volume is occupied by lipofuscin by the age of 80 years (15) . Notably, the lipofuscin fluorophore A2E blocks cholesterol efflux, resulting in the accumulation of both free cholesterol and cholesteryl esters in RPE cells (14) . Further, RPE cells have been shown to express ABCA1, scavenger receptor BI (SR-BI), apolipoprotein A-I (ApoA-I) and apolipoprotein E (ApoE), which participate in the RCT process (16); ABCA1 and ApoE are also associated with susceptibility to AMD (6, 17) . ApoE is synthesized and secreted by RPE cells in considerable amounts comparable to those in the liver and brain, the two most abundant biological synthetic sources of ApoE (18) . ApoE and ApoA-I proteins were detected in drusen and have been implicated in apolipoprotein-mediated RCT in lipid trafficking and in facilitating the efflux of lipids from the RPE, and their transit across Bruch's membrane to the choroidal vasculature (19) .
There have been no previous studies investigating the function of the mitochondrial cholesterol trafficking protein, TSPO, in RPE cells. In this study, we found TSPO to be highly expressed in human RPE (ARPE-19 cell line) and mouse RPE cells. We also found TSPO ligands significantly increased cholesterol efflux to ApoE, ApoA-I and HDL from RPE cells. When TSPO was deleted in RPE cells, TSPO-specific ligand treatment could not increase cholesterol efflux. Aged mouse RPE cells had significantly decreased Tspo expression and impaired cholesterol efflux. Our observations demonstrated that TSPO is involved in regulating cholesterol efflux from RPE cells, suggesting TSPO as a potential therapeutic target for AMD.
Results

TSPO ligands increased cholesterol efflux from RPE cells
Previously reports showed that TSPO, a mitochondrial outer membrane protein, is expressed in fibroblasts, macrophages, microglia and astrocytes (8, (20) (21) (22) (23) (24) (25) . We examined TSPO expression in ARPE-19 cells using a rabbit monoclonal antibody and found TSPO to be present and localized to mitochondria (Fig. 1) Fig. S1 ).
Previous reports demonstrated that TSPO regulated cholesterol efflux in fibroblast and macrophage cells (8, 21) . We treated ARPE-19 cells with TSPO specific ligands for 24 h and found that FGIN-1-27 and XBD173 significantly increased cholesterol efflux to apoE, apoA-I, HDL and human serum (HS), and Etifoxine significantly increased cholesterol efflux to HDL and HS (Fig. 2) .
Ligands of TSPO decreased lipogenesis in RPE cells
We investigated whether treatment of TSPO ligand affected lipogenesis in ARPE-19 cells by measuring the syntheses of phospholipid, triacylglycerol, cholesteryl and fatty acid. We found significantly reduced incorporation of [ (Fig. 3A, B) . By contrast, there was no significant difference when incorporation of [ 14 C]acetate into triglycerides, fatty acid and cholesterol ester pools between ligand-treated and control cells were compared (Fig. 3A, B) . Etifoxine-treated ARPE-19 cells exhibited significant reduction by 57.42% in incorporation of [ 14 C]acetate into the free cholesterol pool compared with the vehicle control; the other examined lipid pools showed no significant changes for the same comparison (Fig. 3C) . We also measured total cholesterol mass and phospholipids in control and ligand treated ARPE-19 cells and found significant reduction in total cholesterol by 35.49, 32.51 and 23.61% in FGIN-1-27, XBD173 and Etifoxine treated cells, respectively (Fig. 3D ) and in phospholipid contents by 29.18 and 9.93% in FGN1-27 and XBD173 treated cells respectively (Fig. 3E) .
Ligands of TSPO increased gene expression of proteins involved in cholesterol transport and metabolism in RPE cells
Since treatment with TSPO ligands influenced cholesterol efflux (Fig. 2) , we examined expression of genes involved in cholesterol homeostasis in ARPE-19 cells that were treated with FGIN-1-27 (10 mM), XBD173 (25 mM) or Etifoxine (20 mM) for 24 h. The mRNA expression levels of these genes relative to housing keeping gene GAPDH were shown in Supplementary Material, Figure S2A . FGIN-1-27 significantly upregulated the expression of NR1H3 (encoding to liver X receptor alpha protein, LXRa), ABCA1, ABCG1 and CYP27A1 but not CYP46A1 (Supplementary Material, Fig. S2A ), while Etifoxine notably enhanced the expression of LXRa, ABCA1, ABCG1 and CYP46A1 except CYP27A1 Every experiment was performed in triplicate and three independent experiments were carried out. NS: non-significant, *P < 0.05, **P < 0.01, ****P < 0.0001. Three independent experiments were performed. **P < 0.01, ***P < 0.001, ****P < 0.0001. Knockout of TSPO in RPE cells using the CRISPER/Cas9 engineering system
Human TSPO gene contains four exons with exon 1 untranslated (Fig. 4A ). To delete TSPO, we followed the protocol of the CRISPR/Cas9 system and designed a guide RNA (gRNA) having sequence complementary to 18 nucleotides (c.87_104) of TSPO exon 2 ( Fig. 4A ). ARPE-19 cells were transfected with the gRNA construct and the Cas9 expression plasmid. Nine colonies were derived from G418 transient selection. Two colonies, named KO1 and KO2, with loss of TSPO were confirmed by Western blotting using a TSPO-specific antibody (Fig. 4B ). Immunocytochemistry further confirmed TSPO was absent from KO1 and KO2 cells (Fig. 4C ). We used Sanger Sequencing to find that KO1 had an insertion of 82 bp (cc.101_102ins82.) and KO2 contained a deletion of 8 bp (c.96_103del8) in the target region of exon 2 (Fig. 4A) . The deletion/insertion mutations resulted in frame-shift reading with truncated peptides (Supplementary Material, Fig. S3 ).
Increased lipid accumulation in TSPO knockout RPE cells
Treatment with TSPO specific ligands enhanced cholesterol efflux in ARPE-19 cells (Fig. 2) . However, when TSPO was deleted, the knockout cells had no significant change in [ 
TSPO
-/-cells were incubated with DiI-OxLDL for 24 h we found intracellular OxLDL were significantly increased in TSPO -/-cells by 39% (P < 0.01) compared to wildtype cells (Fig. 5A , B). We also confirmed significant increase of OxLDL accumulation in TSPO deleted RPE cells using fluorescence-activated cell sorting assay (Fig. 5C ) .We determined whether the increase of OxLDL accumulation was also related oxLDL uptake in TSPO -/-cells, we fed both wildtype and TSPO -/-cells with DiI-OxLDL for 4 h and assessed intracellular oxLDL by confocal imaging and FACS assay. We found that uptake of OxLDL was significantly increased by 34% in TSPO deleted cells (Fig. 5D-E) . Previous data showed uptake of LDL and OxLDL by rodent RPE cells occurs primarily via LDL receptor (LDLR) (26) , which is expressed in both rodent and human RPE cells (26, 27 (Fig. 7A, B) , consistent with early report that deletion of TSPO increased ROS production in steroidogenic cells (31) . Both wildtype and TSPO-deleted RPE cells incubated with OxLDL had marked increase of ROS production at 4 and 24 h when compared to cells cultured in serum-free medium, indicating oxLDL promoted ROS production. In the presence of OxLDL, TSPO -/-cells also had significant increase of ROS production when compared to wildtype RPE cells at 4 and 24 h by 64 and 58% respectively (Fig. 7A, B) . We also measured the secretion of IL-1b and TNFa into the media above wildtype and TSPO-deleted cells by enzyme-linked immunosorbent assay (ELISA). When cultured in serum-free medium, TSPO -/-cells exhibited a trend towards increased output of IL-1b at 4 and 24 h though there was no significant difference compared to wildtype cells. However, TNFa levels were increased in the media above TSPO -/-cells by 37%, with a NS: no significance,* P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. significant difference noted from the wildtype control at 24 h (Fig. 7C, D) . Levels of both IL-1b and TNFa were markedly higher in TSPO -/-cells compared to wiltype cells when incubated with oxLDL at 4 and 24 h (Fig. 7C, D Fig. S5 ).
Reduced TSPO expression and impaired cholesterol efflux in aged mouse RPE cells Wang et al. (2015) examined TSPO localization in developmental and young adult mouse retina and showed TSPO was localized in the developing and migratory microglia at P0, P3 and P7, while the localization in microglia disappeared at P14. At P28 (young adult), TSPO signal was detected only in retinal blood vessels and not in any other retinal cells, however TSPO protein was gradually increased during retinal development with significant high level in young adult retina (25) . We performed immunostaining to detect TSPO expression in the retinas of adult mice (3 months old) and found a marked strong signal in RPE cell layer, and quite a strong signal presented in the ganglion cell layer (Fig. 8A, B) . We also detected TSPO immunopositivity in the choroid, possibly in the choroid vessels. We quantified the expression of Tspo mRNA and protein in mouse retina and RPE/choroid: Tspo mRNA level in RPE/choroid was 20.7 fold higher than that in the retina, TSPO protein level in RPE/choroid was 16.7 fold higher than that in the retina (Fig. 8C-E) . We further investigated TSPO expression in aged mouse RPE and retina: TSPO was significantly decreased by 58.67% at mRNA level and by 24.46% at protein level in 20-month old mouse RPE cells when compared to that of 3-month old RPE cells (Fig. 9A-C) . Expression of the cholesterol transporter genes, Abca1 and particularly Abcg1, in aged RPE was also significantly decreased (Supplementary Material, Fig. S6A ). In aged mouse retina, we also detected significantly declined expression of Tspo, Abca1 and Abcg1 (Supplementary Material, Fig. S6B ).
The total cholesterol mass was measured in 3-month and 20-month old mouse RPE and that the cholesterol mass of 20-month old RPE was significantly higher than that of 3 moth-old RPE/choroid (Fig. 9D) . We therefore investigated whether the increase of total cholesterol in aged RPE is partially due to a defect in cholesterol efflux. We observed that the percentage of [ 3 H]cholesterol efflux to apoE, apoA-I, HDL, or human serum was significantly decreased in 20-months old RPE when compared to that of 3-months old RPE (Fig. 9E) .
Discussion
Extensive clinical studies show abnormal cholesterol accumulation in drusen of AMD patients, implicating dysregulated Data were presented as mean 6 SD. ***P < 0.001. cholesterol homeostasis (32) . Experimental research has demonstrated that impaired cholesterol efflux might contribute to the pathogenesis of AMD (15, 33) . However, the underlying mechanisms are not fully understood. The present study demonstrated that TSPO ligands enhance cholesterol efflux in RPE cells. Deletion of TSPO prevented modulation on cholesterol efflux by TSPO ligands and resulted in markedly increased cholesterol (OxLDL) uptake and accumulation in TSPO -/-RPE cells.
Aged mice had significant decrease in retinal and RPE expression of TSPO and defective cholesterol efflux in aged primary RPE cells. TSPO is an outer mitochondrial membrane (OMM) protein with five transmembrane (TM) helixes and can bind cholesterol at a high affinity through its C-terminal cholesterol recognition amino acid consensus (CRAC) motif to transport cholesterol to the inner mitochondrial membrane (IMM) (34, 35) . TSPO can also bind different ligands, which promote cholesterol movement from OMM to IMM, where cholesterol is converted into pregnenolone by CYP11A1 in steroidogenic tissues or into oxyterols (27-hydroxycholesterol and 5-cholestanoic acid) by CYP27A1 in macrophage and other cell types (34) . Oxysterols can activate a nuclear transcription factor, liver X receptor (LXRa/b), thereby upregulating the transcription of ABCA1, ABCG1 and ABCG4, which promote cholesterol efflux. In ARPE-19 cells, TSPO specific-ligands enhanced the efflux of cholesterol to ApoA-I, apoE and HDL (Fig. 2) and markedly decreased the total cholesterol level, and the biogenesis of free cholesterol (Fig. 3) . Equally, TSPO ligand treatment significantly increased expression of ABCA1, ABCG1 and LXRa (Supplementary Material, Fig.  S2 ). CYP27A1 was localised in human RPE (27) and its expression was significantly increased in RPE cells exposed to TSPO specific ligands FGIN-1-27 or XBD173 (Supplementary Material, Fig. 3 ).
Our data suggested TSPO has similar function in cholesterol efflux in RPE cells possibly through oxyterol activated LXRmediated upregulation of cholesterol transporter genes and down-regulation of cholesterol biosynthesis.
Apolipoprotein-containing lipoproteins accumulate and become oxidized in drusen (36) . Apolipoprotein B100 (apoB100) is the major apolipoprotein of LDL, and oxidized apoB100 and OxLDL localized in drusen (37) . Early data showed OxLDL was internalized by RPE cells, causing a defect in outer segment phagocytosis and induced apoptosis (37) (38) (39) (40) . Recent data demonstrated OxLDL triggered the alternative complement pathway by decreasing complement regulator CD59 and increasing the formation of membrane attack complexes (MACs) in RPE cells (41, 42) . Our experiments indicated that deletion of TSPO enhance OxLDL uptake and accumulation in RPE cells (Fig. 5) , which may contribute to abnormal outer segment phagocytosis and dysfunction of the alternative complement system. Certainly, loss of TSPO caused increased oxidative stress in RPE cells by producing higher level of ROS (Fig. 7A, B) and secretion of IL-1b and TNFa levels was markedly increased in OxLDLtreated TSPO -/-RPE cells (Fig. 7C, D) . When ARPE-19 cells were exposed to IL-1b or TNFa, the expression of LDLR was significantly upregulated (Supplementary Material, Fig. S5 ), which promotes OxLDL uptake. ROS also can oxidatively modify macromolecules such as DNA, protein and lipid and lead to dysfunction of RPE cells. Together, these data suggest that loss of TSPO contributes to both dysregulated cholesterol metabolism and inflammation, and may play a central in the pathogenesis of AMD. TSPO is upregulated in activated microglial cells of different neurodegenerative diseases and recognized as a biomarker for early diagnosis and disease progression (43); TSPO expression was significantly increased at mRNA and protein level in retinal microglial cells by LPS-induced inflammation (23, 25) . TSPO was also strongly upregulated in retinal microglia in models of retinal injury and degeneration (23, 25) . Knockdown of TSPO significantly increased ROS production and TNFa secretion in microglial cells (BV2) in response to LPS challenge; there was no significant increase of ROS production and TNFa expression in knockdown cells without LPS-activation, possibly due to only 30-40% TSPO depletion (23) . In this study, TSPO knockout RPE cells had significant increase in the production of ROS and in secretion of IL-1b and TNFa (Fig. 7C, D) . TSPO ligand (PK-11195 and Ro5-4864) treatment significantly decreased ROS production and TNFa secretion in BV2 cells; intravitreal treatment with a TSPO ligand (TTN) inhibited LPS-induced retinal inflammatory reaction by reducing retinal lipid peroxidation and TNFa protein level (25) . Treatment with another TSPO ligand, XBD173, reduced expression of pro-inflammatory genes and prevented photoreceptor cell death in light-induced retinal degeneration (44) . We also found treatment with TSPO ligands significantly down-regulated expression of pro-inflammatory cytokines in ARPE-19 cells (data not shown). Previous reports showed that TSPO was localized to retinal microglia and inner retinal blood vessels (23, 25) . We found very strong TSPO signal in three-month old mouse RPE cells, less strong signal in the choroid and some weak signals in the inner and outer plexiform layers (possibly the microglia); we also found quite strong signals in ganglion cells (Fig. 8A, B) . Ishikawa et al. reported that increased pressure could upregulate TSPO expression in rat ganglion cells; TSPO was undetectable at 10 mmHg and significantly increased in ganglion cells at 35 mmHg and 75 mmHg respectively (45) . The difference of immunolocalization of TSPO in retina was possibly due to different approaches for preparing immunostaining samples or immunodetection methods. We used qRT-PCR and Western blotting to confirmed higher level of TSPO expression RPE/choroid when compared to the retina (Fig. 8C-E) . During retinal development, Wang et al. detected highest TSPO mRNA level in postnatal 0 (P0) retina, then significantly lower but steadily increased in postnatal age (P0-P28), TSPO protein was also steadily increased in postnatal age (P0-P28) (25) . However, another group found TSPO mRNA was at highest level in P3 retina then continuously decreased to low levels in adult (P60) retinas (23) . We found that TSPO expression was markedly decreased in aged mouse retina and RPE/choroid (Fig. 9A-C, Supplementary  Material, Fig. S6B ). Aged mouse RPE cells had lower level of cholesterol efflux and higher level of total cholesterol (Fig. 9D, E) , which may be in part due to decreased TSPO, which appears to regulate cholesterol efflux in the RPE cells (Fig. 2 and  Supplementary Material, Fig. S4 ).
Prevention of AMD progression is a priority in the long-term care of patients with early stage disease. In pursuit of this objective several strategies are currently being investigated including high-dose lipid lowering therapy (46) and laser-based interventions (47) . Targeting the cholesterol efflux pathway in order to ameliorate and/or reverse subretinal accumulation of lipid with associated RPE dysfunction warrants further investigation. The availability of an approved TPSO ligand therapeutic paves the way for translation to clinical trial. If safety and efficacy are demonstrated this novel approach would usefully impact a key pathway likely to be involved in the complex process of progression from early to late stage AMD. How modification of the TPSO pathway using a biochemical approach or AAV-gene therapy might supplant or supplement other tools in reducing the burden of AMD-related visual loss requires further study.
Further we plan to investigate the role of this pathway in other conditions which show sub-retinal deposits resembling AMD for example late-onset retinal degeneration (48) and Sorsby fundus dystrophy (49) . 
Materials and Methods
Reagents
Cells viability
The 
Measurement of reactive oxygen species (ROS)
Wildtype and TSPO -/-ARPE-19 cells were incubated with OxLDL 
Enzyme-linked immunosorbent assay (ELISA)
The cells were treated with oxLDL (200 mg/ml) for 4 or 24 h. The levels of IL-1b and TNF-a in culture medium were quantified by ELISA with human TNF-a and IL-1b kits (Peprotech, UK) following the manufacturer's protocols.
Uptake of oxidized LDL by RPE cells
Fluorescence-labelled DiI-oxidized LDL (DiI-OxLDL) was purchased from Alfa Aesar, UK. ARPE-19 cells were seeded in 6-well plates and treated with DiI-OxLDL (20 mg/ml) for 4 or 24 h. The treated cells were washed five times with PBS and fixed with 4% PFA for 10 min at room temperature then mounted with Vectashield medium with DAPI (Vector Lab Ltd., Peterborough, UK). The intracellular fluorescence-labelled DiI-OxLDL was visualized by LSM 510 Zeiss confocal microscope (Zeiss) and quantified using Image J.
Flow cytometry
The ARPE-19 cells were treated with DiI-labeled oxidized LDL (20 mg/ml) for 4 and 24 h. Then the cells were washed 3 times with PBS and twice with PBS containing BSA (2 mg/ml). The cells were collected by detachment in trypsin, resuspended with complete medium and centrifuged at 1000 rpm for 5 min and washed two times with PBS. The cells were analyzed by flow cytometry (10 000 events; Excitation, 514 nm; Emission; 550 nm) using a FACSCalibur BD Immunocytometry Systems. The data were analyzed by FlowJo software (Treestar Inc).
Knockout of TSPO in ARPE-19 cells
The clustered regularly interspaced short palindromic repeats (CRISPR) system was employed to knockout the TSPO gene from ARPE-19 cells. The CRISP primers were designed using https:// benchling.com website to targeting exon 2 of TSPO gene (Accession: NC_018933). The CRISP Oligos were extended using Phusion DNA polymerase (New England Biolab, UK) and ligated into linearized gRNA vector (Addgene 41824) using Gibson assembly to generate a CRISP TSPO-gRNA construct, which was confirmed by sequencing. The CRISP TSPO-gRNA construct and Cas9 plasmid (Addgene 41815) were transfected into ARPE-19 cells. TSPO knockout colonies were verified by Western blotting, Sanger sequencing and immunocytochemistry.
Isolation of primary retinal pigment epithelium (RPE) cells from mouse eyes
Eyes from 3-month and 20-month old mice were washed three times in PBS then washed twice in DMEM F-12 medium. The eyes were transferred into HBSS solution and a circular incision was made around the ora serrata of each eye. The lens and retina were removed, the RPE/choroid/sclera was incubated with 2% dispase solution (w/v) in complete medium for 45 min at 37 C with 5% CO 2 . The RPE/choroid/sclera was washed with PBS twice then incubated with trypsin-EDTA at 37 C for 15-20 min.
After incubation the RPE/choroid/sclera was vigorously shaken to detach the RPE cells. The detached RPE cells were cultured in DMEM F-12 medium until they reached confluent.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted from ARPE-19 cells, mouse RPE/choroid, or mouse retinas using Tri Reagent (Sigma, UK) according to the manufacturer's guidance. The cDNA was synthesized by using High Capacity cDNA Reverse Transcription Kit with RNAase inhibitor (Applied Biosystems, UK). The quantification of gene expression was performed by a qRT-PCR assay using a Platinum Syber Green QAPCR Super Mix-UDG w/ROX kit (Invitrigen, UK) with primers for targeted genes.
Immunocytochemistry and immunohistology
Wildtype and TSPO-deleted ARPE-19 cells were incubated with mitochondrial dye, MitoView Green (100 nM, Biotium, USA) in culture medium for 30 min at 37 C. After multiple washes with PBS, the cells were fixed with 4% paraformaldehyde and blocked with 2% sheep serum with 2% BSA in PBS then stained with a primary rabbit monoclonal TSPO antibody (Abcam ab109497, 1:200 dilution) which recognizes human TSPO C-terminal, and with secondary Alexa Fluor 594 secondary antibody. In addition, mouse (three-month old) eyes were fixed with 4% paraformaldehyde in PBS and cryoprotected in Cryomatrix medium (VWR, UK). The eyes were sectioned and mounted on superfrost slides. The sections were blocked with 2% BSA in PBS and incubated with primary and secondary antibodies. Images were captured using a LSM 510 confocal microscope (Zeiss). 
Western blotting
Statistical analysis
Data was analyzed by statistical significance using analysis of variance (ANOVA) and a t-test, followed by appropriate post hoc tests (Bonferroni). As indicated, all data are presented as mean 6 SD and collected from three independent experiments. Statistical analysis was performed using Prism software (version 6.0 from GraphPad Software Inc., San Diego, CA, USA); *P < 0.05, **P < 0.01 and ***P < 0.001, ****P < 0.0001.
Supplementary Material
Supplementary Material is available at HMG online.
